These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12871190)

  • 21. Fc Receptor Variants and Disease: A Crucial Factor to Consider in the Antibody Therapeutics in Clinic.
    Kim J; Lee JY; Kim HG; Kwak MW; Kang TH
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory ITAMs as novel regulators of immunity.
    Blank U; Launay P; Benhamou M; Monteiro RC
    Immunol Rev; 2009 Nov; 232(1):59-71. PubMed ID: 19909356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases.
    Karsten CM; Köhl J
    Immunobiology; 2012 Nov; 217(11):1067-79. PubMed ID: 22964232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoimmune aspects of type 2 diabetes mellitus - a mini-review.
    Itariu BK; Stulnig TM
    Gerontology; 2014; 60(3):189-96. PubMed ID: 24457898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The science and arts of antibodies.
    Gupta S; Schwarz HP
    J Clin Immunol; 2014 Jul; 34 Suppl 1():S1-3. PubMed ID: 24760115
    [No Abstract]   [Full Text] [Related]  

  • 26. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
    Vaccaro C; Zhou J; Ober RJ; Ward ES
    Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.
    Crofford LJ; Nyhoff LE; Sheehan JH; Kendall PL
    Expert Rev Clin Immunol; 2016 Jul; 12(7):763-73. PubMed ID: 26864273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Signaling by Antibodies: Recent Progress.
    Bournazos S; Wang TT; Dahan R; Maamary J; Ravetch JV
    Annu Rev Immunol; 2017 Apr; 35():285-311. PubMed ID: 28446061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoantigen complementarity and its contributions to hallmarks of autoimmune disease.
    Pendergraft WF; Badhwar AK; Preston GA
    J Theor Biol; 2015 Jun; 375():88-94. PubMed ID: 25526886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases.
    Ruiz de Souza V; Kaveri SV; Kazatchkine MD
    Clin Exp Rheumatol; 1993; 11 Suppl 9():S33-6. PubMed ID: 8354005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of antibody production mediated by Fc gamma receptors, IgG binding factors, and IgG Fc-binding autoantibodies.
    Gergely J; Sármay G; Rajnavölgyi E
    Crit Rev Biochem Mol Biol; 1992; 27(3):191-225. PubMed ID: 1587143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IVIG-mediated effector functions in autoimmune and inflammatory diseases.
    Galeotti C; Kaveri SV; Bayry J
    Int Immunol; 2017 Dec; 29(11):491-498. PubMed ID: 28666326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of Fc receptors and complement in autoimmunity.
    Baumann U; Schmidt RE
    Adv Exp Med Biol; 2001; 495():219-25. PubMed ID: 11774570
    [No Abstract]   [Full Text] [Related]  

  • 34. B cell immunobiology in disease: evolving concepts from the clinic.
    Martin F; Chan AC
    Annu Rev Immunol; 2006; 24():467-96. PubMed ID: 16551256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses.
    Ettinger R; Karnell JL; Henault J; Panda SK; Riggs JM; Kolbeck R; Sanjuan MA
    Autoimmunity; 2017 Feb; 50(1):25-36. PubMed ID: 28166684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between immunodeficiency and the development of autoimmune disease.
    Sleasman JW
    Adv Dent Res; 1996 Apr; 10(1):57-61. PubMed ID: 8934926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineered clearing agents for the selective depletion of antigen-specific antibodies.
    Devanaboyina SC; Khare P; Challa DK; Ober RJ; Ward ES
    Nat Commun; 2017 May; 8():15314. PubMed ID: 28561044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signal regulators in FcR-mediated activation of leukocytes?
    Mina-Osorio P; Ortega E
    Trends Immunol; 2004 Oct; 25(10):529-35. PubMed ID: 15364055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches.
    Nimmerjahn F
    J Clin Immunol; 2016 May; 36 Suppl 1():83-7. PubMed ID: 26957094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement Therapeutics in Autoimmune Disease.
    Thurman JM; Yapa R
    Front Immunol; 2019; 10():672. PubMed ID: 31001274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.